Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAMEO-SEMA
NCT05371496Phase 4Completed
- Sponsor
- Mayo Clinic
- Start
- Sep 2022
- Primary completion
- Jul 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) and obesity comparing Semaglutide Treatment with Placebo Treatment (2 arms). Primary endpoint: Pulmonary Capillary Wedge Pressure at 12 months. Started Sep 2022; status: completed.
02
Drugs
03
Conditions
heart failure with preserved ejection fraction (HFpEF)obesity
Beyond the preview
Go deeper on NCT05371496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05371496.